Alliance Pharma plc
Alliance Pharma plc, a holding company, acquires, markets, and distributes consumer healthcare products and prescription medicines in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. It provides its products under the Aloclair, Anbesol, Asthon & Parsons, Forceval, Hydromol, Kelo-Cote, MacuShield, Vamousse, Nizoral, and Amberen brand names. The company was incorporated i… Read more
Alliance Pharma plc (APH) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: 0.099x
Based on the latest financial reports, Alliance Pharma plc (APH) has a cash flow conversion efficiency ratio of 0.099x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX20.47 Million) by net assets (GBX207.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Alliance Pharma plc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Alliance Pharma plc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Alliance Pharma plc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Alliance Pharma plc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MARKS & SPENCER - Dusseldorf Stock Exchang
DU:MA6
|
0.091x |
|
Reunert Ltd
OTCMKTS:RNRTF
|
N/A |
|
JANOSCH F&M
BE:JFIK
|
N/A |
|
B2GOLD
MU:5BG
|
-0.005x |
|
BORANA
NSE:BORANA
|
N/A |
|
CRMSN WN GRP-WI
BE:CSW
|
0.025x |
|
Mountview Estates PLC
LSE:MTVW
|
0.060x |
|
BCHQ39
SA:BCHQ39
|
N/A |
Annual Cash Flow Conversion Efficiency for Alliance Pharma plc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Alliance Pharma plc from 1999 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX207.64 Million | GBX38.72 Million | 0.186x | +29.33% |
| 2023-12-31 | GBX217.87 Million | GBX31.41 Million | 0.144x | +97.75% |
| 2022-12-31 | GBX287.66 Million | GBX20.97 Million | 0.073x | -46.73% |
| 2021-12-31 | GBX282.49 Million | GBX38.66 Million | 0.137x | -7.50% |
| 2020-12-31 | GBX280.96 Million | GBX41.57 Million | 0.148x | +13.44% |
| 2019-12-31 | GBX274.18 Million | GBX35.76 Million | 0.130x | +48.36% |
| 2018-12-31 | GBX252.20 Million | GBX22.17 Million | 0.088x | -32.75% |
| 2017-12-31 | GBX203.38 Million | GBX26.58 Million | 0.131x | +38.44% |
| 2016-12-31 | GBX179.26 Million | GBX16.93 Million | 0.094x | +92.29% |
| 2015-12-31 | GBX162.44 Million | GBX7.98 Million | 0.049x | -69.58% |
| 2014-12-31 | GBX70.78 Million | GBX11.42 Million | 0.161x | +4.05% |
| 2013-12-31 | GBX64.67 Million | GBX10.03 Million | 0.155x | -35.33% |
| 2012-12-31 | GBX51.85 Million | GBX12.44 Million | 0.240x | +21.38% |
| 2011-12-31 | GBX44.13 Million | GBX8.72 Million | 0.198x | -52.14% |
| 2010-12-31 | GBX36.08 Million | GBX14.89 Million | 0.413x | -10.77% |
| 2009-12-31 | GBX16.63 Million | GBX7.69 Million | 0.463x | +55.02% |
| 2008-12-31 | GBX8.77 Million | GBX2.62 Million | 0.298x | +16.83% |
| 2007-12-31 | GBX6.67 Million | GBX1.70 Million | 0.255x | +392.87% |
| 2006-12-31 | GBX10.43 Million | GBX-910.00K | -0.087x | -281.83% |
| 2005-12-31 | GBX7.50 Million | GBX360.00K | 0.048x | +229.42% |
| 2005-02-28 | GBX6.83 Million | GBX-253.00K | -0.037x | +93.01% |
| 2004-02-29 | GBX2.23 Million | GBX-1.18 Million | -0.530x | +89.46% |
| 2003-02-28 | GBX-194.00K | GBX976.00K | -5.031x | -13921.47% |
| 2002-12-31 | GBX2.24 Million | GBX-80.26K | -0.036x | +97.21% |
| 2002-02-28 | GBX538.00K | GBX-692.00K | -1.286x | -3926.58% |
| 2001-02-28 | GBX595.00K | GBX20.00K | 0.034x | -95.49% |
| 2000-02-29 | GBX451.00K | GBX336.00K | 0.745x | -93.85% |
| 1999-02-28 | GBX114.00K | GBX1.38 Million | 12.114x | -- |